Efficacy and safety of switching to <scp>iGlarLixi</scp> from premixed insulins in people with type 2 diabetes: The Soli‐ <scp>SWITCH</scp> study
iGlarLixi initiation was associated with improved glycaemic control, without body weight gain or increased hypoglycaemia over 24 weeks.
Authors
- Soo Kyung Lim (ORCID: https://orcid.org/0000-0002-4137-1671)
- Okan Bakıner (ORCID: https://orcid.org/0000-0001-9038-8376)
- Felipe Lauand
- Martin Haluzı́k (ORCID: https://orcid.org/0000-0002-0201-6888)
- Katarzyna Cypryk (ORCID: https://orcid.org/0000-0003-0877-9111)
- Agustina Alvarez
Institutions
- Başkent University (TR)
- Seoul National University Bundang Hospital (KR)
- Sanofi (France) (FR)
- Sanofi (Spain) (ES)
- Medical University of Lodz (PL)
- Institute of Clinical and Experimental Medicine (CZ)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1111/dom.16276
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Sanofi